ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.

Michael MarisGilles SallesWon Seog KimTae Min KimRoger M LyonsMartha ArellanoReem KarmaliGary SchillerElizabeth CullCamille N AbboudConnie BatleviIoannis KagiampakisMarlon C RebelattoYoung LeeLyndon C KirbyFujun WangJohn BothosDanielle M TownsleyAmir T FathiVincent Ribrag

Published in: Targeted oncology (2024)

Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).

Keyphrases

open label
endothelial cells
cancer therapy
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
pluripotent stem cells
drug delivery